Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb 21:18:2601-2611.
doi: 10.2147/JIR.S496735. eCollection 2025.

IL-6 and CD4+/CD8+ are Important Indicators for Predicting Prognosis in Elderly AECOPD Patients: A Retrospective Study

Qingqing Liu #  1   2 , Yanhui Wang #  1   2 , Xueshuai Cao  1   2 , Shan Zhang  1   2 , Juan Xie  1   2
Affiliations

IL-6 and CD4+/CD8+ are Important Indicators for Predicting Prognosis in Elderly AECOPD Patients: A Retrospective Study

Qingqing Liu et al. J Inflamm Res. .

Abstract

Purpose: Evaluating the role of IL-6 and CD4+/CD8+ in predicting the prognosis of elderly patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD).

Patients and methods: This study retrospectively enrolled 413 elderly patients who were hospitalized for AECOPD between January 2019 and December 2021. Patients were divided into event and non-event groups based on whether they were readmitted or died due to AECOPD during 18 months of follow-up. The associations between IL-6 and CD4+/CD8+ with adverse events were assessed using Cox proportional hazards regression models, Kaplan-Meier survival analysis, and restricted cubic spline (RCS) models. Additionally, subgroup analyses were conducted to evaluate the stability of these associations, and ROC curves were used to assess the predictive ability of IL-6 combined with CD4+/CD8+ for adverse events.

Results: A total of 413 patients were included in the study, with 218 experiencing adverse events. Patients with high levels of IL-6 and low levels of CD4+/CD8+ had a higher risk of adverse events. There was a non-linear relationship between IL-6 and CD4+/CD8+ with adverse events (p<0.05). Subgroup analyses further confirmed the robustness of this association. ROC curve analysis indicated that combining IL-6 with CD4+/CD8+ significantly improved the predictive value for adverse events.

Conclusion: There is a non-linear relationship between IL-6 and CD4+/CD8+ and adverse events in elderly patients with AECOPD. Combining IL-6 with CD4+/CD8+ ratios significantly enhances the predictive value for adverse events.

Keywords: CD4+/CD8+; IL-6; acute exacerbation of chronic obstructive pulmonary disease; elderly; prognosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest related to this study.

Figures

Figure 1
Figure 1
Flowchart of patients enrolled in the study.
Figure 2
Figure 2
Survival curves of AECOPD patients at 18-month follow-up. (A) grouped by quartiles of IL-6; (B) grouped by quartiles of CD4+/CD8+.
Figure 3
Figure 3
Dose–response relationship between IL-6 or CD4+/CD8+ and adverse events in elderly patients with AECOPD from RCS analysis. IL-6 and adverse events (A); CD4+/CD8+ and adverse events (B).
Figure 4
Figure 4
Hazard ratios of the IL-6 for predicting adverse events in the subgroup analysis.
Figure 5
Figure 5
Hazard ratios of the CD4+/CD8+ for predicting adverse events in the subgroup analysis.
Figure 6
Figure 6
ROC curves for the prediction of adverse events. The basic model vs +the IL-6+ CD4+/CD8+ in the elderly patients.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2019 Report). Global initiative for chronic obstructive lung disease.
    1. Wang X, Jiang Y. Disease burden of chronic obstructive pulmonary disease in the BRICS countries from 1990 to 2019. Chin Gen Pract. 2024;27(09):1118–1125.
    1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442. doi:10.1371/journal.pmed.0030442 - DOI - PMC - PubMed
    1. Pantzaris ND, Spilioti DX, Psaromyalou A, Koniari I, Velissaris D. The use of serum procalcitonin as a diagnostic and prognostic biomarker in chronic obstructive pulmonary disease exacerbations: a literature review update. J Clin Med Res. 2018;10(7):545–551. doi:10.14740/jocmr3458w - DOI - PMC - PubMed
    1. Antonescu-Turcu AL, Tomic R. C-reactive protein and copeptin: prognostic predictors in chronic obstructive pulmonary disease exacerbations. Curr Opin Pulm Med. 2009;15(2):120–125. doi:10.1097/MCP.0b013e3283218603 - DOI - PubMed

LinkOut - more resources